The president and chief executive officer of Tosk, Inc., Brian Frenzel oversees a company that creates drugs that reduce the side effects of prescription medications. Moreover, Brian Frenzel also serves as a director at the biotechnology firm, SanBio, Inc.

2.  The president and chief executive officer of
Tosk, Inc., Brian Frenzel oversees a company
that creates drugs that reduce the side effects
of prescription medications. Moreover, Brian
Frenzel also serves as a director at the
biotechnology firm, SanBio, Inc.
Headquartered in Mountain View, California,
SanBio discovers and develops therapies for
patients suffering from neurodegenerative
diseases. The firm has recently completed
Phase 1/2a human clinical trials for its SB623 cell
therapy for patients suffering disability as a
result of ischemic stroke.

3.  The studies were conducted at Stanford
University Medical Center in Palo Alto,
California and the University of Pittsburgh
medical center in Pittsburgh, Pennsylvania. The
subjects in the study were 18 chronic and
stable patients who had an ischemic stroke
between six months and five years prior to
SB623 treatment. Researchers delivered three
doses of the medication in an open-label,
staggered escalation paradigm.
The primary objective of the study was to
demonstrate the safety of the pharmaceutical
product.

4.  Operating under a two-year time frame,
SanBio used periodic MRIs and measured
humoral and cell-mediated immunological
function to test the drug against FDA and
WHO safety criteria. The study’s secondary
goal was to observe improvement in motor,
sensory, and cognitive ability following
stroke. These results were analyzed based
on the European and National Institutes of
Health Stroke Scales and Modified Rankin
Score. The company also used FDG-PET
scans to test for changes in brain
metabolism.